Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Patent metadata

Field	Value
Publication number	US-10407493-B2
Application number	US-201916275936-A
Country	US
Kind code	B2
Filing date	Feb 14, 2019
Priority date	Mar 17, 2009
Publication date	Sep 10, 2019
Grant date	Sep 10, 2019

Abstract

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

First claim

What is claimed is:

1. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 126, 127 and 45 and (b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 123, 124 and 7.

2. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 97, 95 and 41 and (b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 88, 89 and 6.

3. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30 and (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 28.

4. An isolated and non-naturally occurring polynucleotide comprising (a) a light chain variable region comprising the nucleotide sequence of SEQ ID NO: 125 and (b) a heavy chain variable region comprising the nucleotide sequence of SEQ ID NO: 122.

5. An isolated and non-naturally occurring polynucleotide encoding (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12.

6. An isolated and non-naturally occurring polynucleotide comprising (a) a light chain variable region comprising the nucleotide sequence of SEQ ID NO: 100 and (b) a heavy chain variable region comprising the nucleotide sequence of SEQ ID NO: 99.

7. The polynucleotide of any one of claims 1 - 6 , wherein the polynucleotide is a single-stranded DNA, a double-stranded DNA or an RNA molecule.

8. The polynucleotide of claim 7 , wherein the single-stranded DNA is a coding or antisense DNA, the double-stranded DNA is a genomic, cDNA or synthetic DNA and the RNA molecule is an hnRNA or a mRNA.

9. One or more vectors encoding the nucleic acid sequence of any one of claims 1 - 6 .

10. The one or more vectors of claim 9 , wherein one vector encodes the light chain sequence and another vector encodes the heavy chain sequence.

11. The one or more vectors of claim 9 , wherein one vector encodes the light chain sequence and a heavy chain sequence.

12. The one or more vectors of claim 9 , wherein the vector is viral vector, a plasmid vector, a plant expression vector or a yeast expression vector.

13. The one or more vectors of claim 12 , wherein the viral vector is an adeno-associated virus vector.

14. A cell containing and expressing the one or more vectors of claim 9 .

15. The cell of claim 14 , wherein the cell is a prokaryotic host cell or a eukaryotic host cell.

16. The cell of claim 15 , wherein the prokaryotic host cell is Escherichia coli , the eucaryotic host cell is a yeast cell, an animal cell or a plant cell.

17. The eucaryotic host cell of claim 16 , wherein the yeast cell is Saccharomyces cerevisiae, Schizosaccharomyces pombe , or Pichia pastoris , the animal cell is a mammalian cell, or hybridoma cell and the plant cell is a tobacco, a corn cell, a soybean cell, or a rice cell.

18. The eucaryotic host cell of claim 17 , wherein the mammalian cell is a CHO cell, a COS cell, a HEK293T cell, a PER.C6 cell, a myeloma cell or a hybridoma cell.

19. A pharmaceutical composition comprising the polynucleotide of any one of claims 1 - 6 and a pharmaceutically acceptable excipient.

20. A method of inhibiting HIV in a host comprising administering to the host a pharmaceutical composition of claim 19 under conditions whereby the polynucleotide or the vector expresses the antibody.

Assignees

• Theraclone Sciences Inc
• Int Aids Vaccine Initiative
• Scripps Research Inst

Inventors

• Chan-Hui Po-Ying
• Frey Steven
• Olsen Ole
• Mitcham Jennifer
• Moyle Matthew
• Phogat Sanjay K
• Burton Dennis R
• Walker Laura Marjorie
• Poignard Pascal Raymond Georges
• Koff Wayne
• Simek-Lemos Melissa Danielle De Jean De St Marcel
• Kaminsky Stephen

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• A61K2039/505

  comprising antibodies · CPC title